Monoclonal Antibodies to the Tumor-Specific Antigen, Human ROR1
Posted Aug 16 2012 8:00pm
Description of Invention: B-cell chronic lymphocytic leukemia (B-CLL) is an incurable disease developed by more than 15,000 Americans each year and currently, there are no therapeutic monoclonal antibodies (mAbs) that specifically recognize B-CLL tumor cells. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a constitutively expressed tumor-specific cell surface antigen and an ideal target for therapeutic antibodies.
Available for licensing are mouse anti-human ROR1 monoclonal antibodies (hybridomas designated 2D11, 1A1, and 1A7). All mAbs bind to ROR1 on the surface of primary human B-CLL cells and have good potential for therapeutic development by either humanization, conversion to chimeric mouse/human antibodies, or conjugation to a radioisotope, chemical drug or bacterial toxin to B-CLL and breast cancer.
Therapeutic antibodies against ROR1-expressing cancers like B-CLL and possibly other hematologic and solid malignancies
Research tools for the study of ROR1 in cancer biology
Collaborative Research Opportunity: The National Cancer Institute, Experimental Transplantation and Immunology Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize diagnostic or therapeutic mAbs against ROR1. Please contact John D. Hewes, Ph.D. at 301-435-3121 or email@example.com for more information.
For Licensing Information Please Contact: Jennifer Wong NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: firstname.lastname@example.org Phone: 301-435-4633 Fax: 301-402-0220